Weather

65°F5:06 AM

Health

1 read

FDA Fast-Tracks Approval for Psychedelic Drugs in Mental Health Treatment

KVIA•Friday, April 24, 2026 at 2:53 PM•CNN Newsource

Medical stethoscope representing healthcare news

Want the full story?

Read the complete article at KVIA

AI Summary

The FDA has expedited the review process for several psychedelic drugs aimed at treating mental health conditions, including psilocybin for treatment-resistant depression and PTSD. This initiative, part of a pilot program, could significantly reduce the time these treatments take to reach patients. A recent executive order from President Trump mandates the FDA to prioritize these therapies and includes a $50 million investment for state studies on their benefits. As the FDA continues to authorize clinical trials for psychedelics like ibogaine, the potential for these drugs to address the mental health crisis in the U.S. is gaining attention, particularly for veterans and those with severe mental health issues. However, the FDA warns that these substances, classified as Schedule I drugs, will only be available in controlled clinical settings if approved.

Key Details: • FDA granted priority review for psilocybin and methylon for mental health treatment. • Executive order from President Trump emphasizes fast-tracking psychedelic drug approvals. • A $50 million investment will support state-level studies on psychedelics. • Psychedelics remain classified as Schedule I drugs, requiring controlled administration.

health trump mental-health fda psychedelics

People & Organizations

Donald TrumpFDARobert F. Kennedy Jr.Marty MakaryMelissa LavasaniCoalición de Medicina Psicodélica

Related Articles

DEA Agent Explains Lab's Involvement in Deadly New Mexico Opioid Case

In a recent discussion, Jeffrey Castillo, the Assistant Special Agent in Charge of the DEA in El Paso, detailed the laboratory's critical involvement in a New Mexico investigation linked to a tragic incident that resulted in three fatalities due to opioid exposure. This case highlights the ongoing opioid crisis affecting the region and the role of federal agencies in addressing such public health emergencies. Castillo's insights underscore the importance of forensic analysis in understanding the circumstances surrounding these deaths and the broader implications for drug enforcement efforts in the area.

House Democrats Report USAID Cuts Linked to Preventable Deaths in Ebola Crisis

A recent report from House Oversight Democrats highlights that the Trump administration's decision to dismantle the U.S. Agency for International Development (USAID) has been linked to approximately 600,000 preventable deaths. The report, released on Thursday, emphasizes that this move hindered the global response to the recent Ebola outbreak and allowed U.S. adversaries to gain influence in developing nations. This situation underscores the critical role of USAID in managing health crises and international relations.

El Paso Patients Gain Local Access to Advanced Cancer Treatment Options

University Medical Center of El Paso (UMC) and Texas Tech Health El Paso have partnered to offer Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for patients with specific abdominal cancers. This advanced treatment, which combines heated chemotherapy with surgery, is now available locally, reducing the need for patients to travel for specialized care. This expansion is significant as it enhances cancer treatment options in the region, potentially improving outcomes for local patients. The collaboration aims to provide comprehensive care and support for those affected by cancer in El Paso.

DEA Highlights Dangers of Fentanyl Mixed with New Synthetic Drugs in El Paso

The DEA has issued a warning about the growing threat of illicit fentanyl combined with various synthetic drugs, which are increasingly appearing in the drug market. These mixtures, including substances like xylazine and nitazenes, pose a heightened risk of fatal overdoses due to their extreme potency and the fact that users may be unaware of their presence in counterfeit pills. Since 2020, the DEA has identified 22 unique nitazenes, most of which are classified as Schedule I controlled substances. The agency emphasizes the importance of public awareness and safety measures, advising individuals to avoid unprescribed medications, carry naloxone, and call 911 in case of suspected overdoses. The situation is evolving rapidly, making community education vital.